NewAmsterdam Pharma

formerly NewAmsterdam Pharma Company N.V.IPO

Science-Backed. Patient-Focused.

NewAmsterdam Pharma was founded in 2019, is headquartered in Naarden, Netherlands, lists 51–200 employees, and has $196.0M in recorded funding across 1 round.

Headquarters
Naarden
Employees
51–200
Founded
2019
Business Model
B2B
Total Funding
$196.0M
Last Round
$196.0M Series AJan 2021
Rounds
1
Type
Public

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 1 funding round and 4 investors for this company. The full record is or through the API.

About

NewAmsterdam Pharma is a Nasdaq-listed, science-backed biopharmaceutical company advancing a new era of treatment for cardiovascular disease and other lipid-related conditions. The company is investigating a novel mechanism of action — cholesteryl ester transfer protein (CETP) inhibition — through its lead investigational asset, obicetrapib, designed to help patients lower LDL-C cholesterol and reduce cardiovascular risk when existing lipid-lowering therapies are insufficient. Its pipeline also extends into Alzheimer's-related research presented at major scientific conferences.

Summary

NewAmsterdam Pharma is a Biotech company based in Naarden, Netherlands, founded in 2019. It lists 51–200 employees. It has raised $196.0M in total across 1 round, most recently a $196.0M Series A round in Jan 2021. Investors include Frazier LifeSciences Acquisition Corporation, Frazier Healthcare and Bain Capital Life Sciences.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding & Exit History

Post-IPO EquityPublic OfferingDec 2024
$479.0M

Sign up to see all 5 events

Funding: Series A. Amounts, valuations, and investors where available.

Investors

Similar Companies

Tiantan Biological / China Biologic (泰邦生物集团)

China's leading blood products manufacturer

Beijing, China1001–5000Biotech, Healthcare
Growth EquityTotal funding$5.1BAug 2022
Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.0BMay 2017
BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

NewAmsterdam Pharma on Indexed.vc
<a href="https://indexed.vc/companies/newamsterdam-pharma"><img src="https://indexed.vc/api/badge/company/newamsterdam-pharma" alt="NewAmsterdam Pharma on Indexed.vc" width="260" height="76" /></a>